Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16914415 | 0.85 | USP2 (0.50) | USP2SMN1; SMN2AVPR1ARECQLKDM4E | |
| SCHEMBL29243603 | 0.84 | USP2 (0.44) | USP2SMN1; SMN2AVPR1ARECQLACACB | |
| SCHEMBL22814430 | 0.79 | USP2 (0.46) | USP2SMN1; SMN2AVPR1ARECQLKDM4E | |
| SCHEMBL31283114 | 0.78 | USP2 (0.45) | USP2SMN1; SMN2RECQLKDM4EMAPT | |
| SCHEMBL31282986 | 0.78 | USP2 (0.40) | USP2SMN1; SMN2AVPR1ARECQLACACB | |
| SCHEMBL23002541 | 0.77 | USP2 (0.44) | USP2SMN1; SMN2AVPR1ARECQLKDM4E | |
| SCHEMBL4069310 | 0.77 | AVPR1A (0.39) | USP2SMN1; SMN2AVPR1ARECQLACACB | |
| SCHEMBL1002845 | 0.77 | AVPR1A (0.39) | USP2SMN1; SMN2AVPR1AACACBDDB1 | |
| SCHEMBL4067697 | 0.77 | CRBN (0.40) | USP2SMN1; SMN2AVPR1AACACBKDM4E | |
| SCHEMBL2428542 | 0.77 | USP2 (0.46) | USP2SMN1; SMN2RECQLKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152574-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. | 2025-05-15 | — | — | US | disclosed |
| CN-119731156-A | Emopanamide binding protein inhibitors and uses thereof | 渤健马萨诸塞州股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| EP-4479384-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | Biogen MA Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2023154499-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154499-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-11649245-B2 | Cyclopropylamine compound as LSD1 inhibitor and use thereof | HELIOEAST PHARMACEUTICAL CO., LTD. (CN) | 2023-05-16 | — | — | US | disclosed |
| US-11649245-B2 | Cyclopropylamine compound as LSD1 inhibitor and use thereof | HELIOEAST PHARMACEUTICAL CO., LTD. (CN) | 2023-05-16 | — | — | US | disclosed |
| US-20220119401-A1 | CYCLOPROPYLAMINE COMPOUND AS LSD1 INHIBITOR AND USE THEREOF | HELIOEAST SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2022-04-21 | — | — | US | disclosed |
| EP-3851440-A1 | CYCLOPROPYLAMINE COMPOUND AS LSD1 INHIBITOR AND USE THEREOF | Medshine Discovery Inc. (CN) | 2021-07-21 | — | — | EP | disclosed |
| WO-2020052649-A1 | CYCLOPROPYLAMINE COMPOUND AS LSD1 INHIBITOR AND USE THEREOF | 南京明德新药研发有限公司 | 2020-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119401-A1 | CYCLOPROPYLAMINE COMPOUND AS LSD1 INHIBITOR AND USE THEREOF | KDM1B, KDM1A, KDM7A | USP2 516/4885SMN1; SMN2 1937/4885AVPR1A 4084/4885 |
| US-11649245-B2 | Cyclopropylamine compound as LSD1 inhibitor and use thereof | KDM1B, KDM1A, KDM7A | USP2 516/4885SMN1; SMN2 1937/4885AVPR1A 4084/4885 |
| US-20250152574-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | EBPL, EBP, CREBBP | USP2 3261/4885SMN1; SMN2 1668/4885AVPR1A 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.